Financial reports
ARS
2023 FY
Annual report to shareholders
12 Apr 24
10-K
2023 FY
Annual report
7 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
13 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
2 Aug 22
Current reports
8-K
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
8-K
Other Events
13 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
15 Dec 23
8-K
Entry into a Material Definitive Agreement
14 Dec 23
8-K
Other Events
6 Dec 23
8-K
Other Events
28 Nov 23
8-K
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
9 Nov 23
8-K
Other Events
1 Nov 23
8-K
Other Events
30 Oct 23
8-K
Other Events
26 Sep 23
Registration and prospectus
S-3
Shelf registration
9 Nov 23
SC TO-I/A
Issuer tender offer statement (amended)
17 Jul 23
SC TO-C
Information about tender offer
15 Jun 23
SC TO-I
Issuer tender offer statement
15 Jun 23
424B5
Prospectus supplement for primary offering
24 May 23
424B5
Prospectus supplement for primary offering
23 May 23
S-8
Registration of securities for employees
10 Mar 22
424B5
Prospectus supplement for primary offering
26 Oct 21
424B5
Prospectus supplement for primary offering
17 Dec 20
424B5
Prospectus supplement for primary offering
15 Dec 20
Proxies
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
DEFA14A
Additional proxy soliciting materials
13 Apr 23
DEF 14A
Definitive proxy
13 Apr 23
PRE 14A
Preliminary proxy
31 Mar 23
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEFA14A
Additional proxy soliciting materials
12 Apr 22
DEF 14A
Definitive proxy
12 Apr 22
DEFA14A
Additional proxy soliciting materials
6 Apr 21
DEF 14A
Definitive proxy
6 Apr 21
Other
EFFECT
Notice of effectiveness
20 Nov 23
CORRESP
Correspondence with SEC
15 Nov 23
UPLOAD
Letter from SEC
15 Nov 23
SEC STAFF
SEC staff action: Order
23 Mar 21
SEC STAFF
SEC staff action: Order
23 Feb 21
EFFECT
Notice of effectiveness
18 Nov 20
CORRESP
Correspondence with SEC
13 Nov 20
UPLOAD
Letter from SEC
13 Nov 20
EFFECT
Notice of effectiveness
25 Oct 19
CERT
Certification of approval for exchange listing
23 Oct 19
Ownership
4
Molly Henderson
10 Apr 24
SC 13D/A
TAKEDA PHARMACEUTICAL CO LTD
10 Apr 24
SC 13D/A
TAKEDA PHARMACEUTICAL CO LTD
1 Apr 24
4
Terrie Curran
26 Mar 24
SC 13G/A
Carlyle Group Inc.
12 Feb 24
SC 13G/A
Invesco Ltd.
9 Feb 24
3
Initial statement of insider ownership
26 Jan 24
SC 13G/A
Medicxi Growth I LP
26 Jan 24
4
Change in insider ownership
25 Jan 24
SC 13D/A
TAKEDA PHARMACEUTICAL CO LTD
25 Jan 24